PATENT CLAIM ANALYSIS

Application Number: 15951929
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "134100"]

Abstract:
The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant follistatin protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.

Claim (Index 14):
The method of  claim 1 , wherein the recombinant follistatin protein is fused to an Fc domain.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 91.0
- Lexical Diversity: 1.4
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14762373', '15075051', '15081629', '14254560', '12893976']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7781393913389771
- 35 USC 102 Novelty (BERT): 0.6420166294943236
- Combined Prediction Score: 0.7645271151545119
- Mean Citation Score: 463.8713
- Max Citation Score: 744.8266
- Similarity Product: 550.4953757703066

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test